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Endothelin receptor antagonists are approved for the treatment
of pulmonary hypertension. The efforts to approve this class of drugs
for renal indications, however, failed so far. Preclinical studies were
promising. Transgenic overexpression of ET-1 or ET-2 in rodents causes
chronic renal failure in a blood pressure independent manner. Blocking
in particular the ETA receptor was effective in the treatment of rodent
models of renal failure such as rats with 5/6 nephrectomy, L-NAME
induced renal failure and diabetic nephropathy. On the other hand,
various animal studies indicate that blocking the renal tubular ETA
and ETB receptormay causewater and salt retention partially mediated
via the epithelial sodium transporter (ENaC) in tubular cells. Endo-
thelin receptor antagonists were successfully tested clinically in renal
indications in phase 2 trials for the treatment of diabetic nephropathy.
They showed efﬁcacy in terms of reducing albumin excretion in patients
with diabetic nephropathy on top of guideline based background
therapy (angiotensin II receptor blockade). However, these promising
results could not be translated to successful phase III trials so far.
The spectrum of serious adverse events was similar to other phase III
trials using endothelin receptor antagonists. We will discuss potential
underlying reasons for these failures and what could be done in the
future. The lessons learned in renal indications are also important
for other potential indications of endothelin receptor antagonists like
cancer and heart failure.
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Endothelin receptor antagonists have been used in clinical trials to
test their renoprotection properties in patients with type 2 diabetes who
do not invariably respond to angiotensin II blockers. Thus, combined
treatment with ET-1 antagonists on top of angiotensin II blockers could
represent an effective tool to reduce blood pressure and ameliorating
renal function. Here we tested the effect of combined treatment with
daglutril, a combined endothelin-converting-enzyme and neutral endo-
peptidase (MME) inhibitor on top of losartan (100 mg/day) in patients
with type 2 diabetes. The randomised, crossover trial was held in two
hospitals in Italy. Eligibility criteria were: age 18 years or older, urinary
albumin excretion 20–999 μg/min, systolic blood pressure (BP) less
than 140 mmHg, and diastolic BP less than 90 mmHg. Patients were
randomly assigned (1:1) with a computer-generated randomized
sequence to receive either daglutril (300 mg/day) then placebo for
8 weeks each or vice versa, with a 4-weekwashout period. The primary
endpoint was 24-h urinary albumin excretion in the intention-to-treat
population. Secondary endpoints were median ofﬁce and ambulatory
(24 h, daytime, and night-time) BP, renal haemodynamics and sieving
function, and metabolic and laboratory test results. This study is
registered with ClinicalTrials.gov, number NCT00160225. 58 patients
were screened, ofwhom45were enrolled (22 assigned to daglutril then
placebo, 23 to placebo then daglutril) and42 (20 vs 22)were included in
the primary analysis. Daglutril did not signiﬁcantly affect 24-h urinary
albumin excretion compared with placebo (p = 0.559). 34 patients had
complete 24-h BP readings; compared with placebo, daglutril signiﬁ-
cantly reduced ambulatory systolic (p = 0.0013), diastolic (p = 0.015),
pulse (p= 0.019), and mean (p= 0.003) BP, as well as all night-time
BP readings and daytime systolic, pulse, and mean BP, but not diastolic
BP. Compared with placebo, daglutril also signiﬁcantly reduced ofﬁce
systolic BP (p = 0.028), but not diastolic, pulse, or mean BP, and in-
crease big endothelin serum concentration. Three patients taking
placebo and six patients taking daglutril had mild treatment-related
adverse events — the most common was facial or peripheral oedema
(in four patients taking daglutril).Our data suggest that daglutril im-
proved control of BP in hypertensive patients with type 2 diabetes and
nephropathy particularly as for systolic hypertension, that in patients
with diabetes and renal involvement is often resistant to treatment. The
treatment effect of daglutril was larger during night time, which is of
major clinical relevance, since night time hypertension is a strong
cardiovascular risk factor in this patient population. We also found that
daglutril on top of full dose losartan had a very good safety proﬁle.
doi:10.1016/j.lfs.2013.12.225
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Introduction and Aims: Patients with type 2 diabetes and albumin-
uria have high cardiorenal morbidity and mortality. We evaluated
whether atrasentan, a selective endothelin receptor A antagonist, could
reduce albuminuria in use with renin angiotensin system inhibitors
(RASi). Methods: 211 subjects with type 2 diabetes, macroalbuminuria,
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